Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma
- Registration Number
- NCT06191744
- Lead Sponsor
- Genmab
- Brief Summary
Follicular lymphoma (FL) is the second most common B-cell cancer and the most common type of cancer of lymphocytes. Unfortunately, this disease is incurable with conventional treatment and the disease recurs in almost all patients. This study will assess how safe and effective epcoritamab is in combination with lenalidomide and rituximab (R2) in treating adu...
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- All
- Target Recruitment
- 1080
-
Diagnosis of follicular lymphoma (FL).
-
Have CD20+, histologically confirmed classic FL (previously Grade 1 to 3a FL) at most recent representative tumor biopsy based on the local pathology report, according to the 5th edition of World Health Organization (WHO) Classification of Haematolymphoid Tumours.
-
Are willing and able to comply with procedures required in the protocol.
-
Must have stage, II, III or IV disease.
-
Must be in need of systemic treatment per investigator, as evidenced by meeting at least one of the Groupe d'Etude des Lymphomes Folliculaire (GELF) criteria.
-
Has one or more target lesions:
- A positron emission tomography (PET)/computerized tomography (CT) scan demonstrating PET-positive lesion(s), and
- >=1 measurable nodal lesion (long axis >1.5cm) or >=1 measurable extra-nodal lesion (long axis >1.0 cm) on CT scan or MRI
-
Eastern Cooperative Oncology Group (ECOG) performance status 0-2.
-
Able to receive at least one of the standard of care chemoimmunotherapy (CIT) treatment regimens: [Arm B] at the discretion of the Investigator, and rituximab and lenalidomide (R2) [Arm C].
-
Have laboratory values meeting the criteria in the protocol.
- Had major surgery within 4 weeks prior to randomization.
- Have active cytomegalovirus (CMV) disease.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Arm A: Epcoritamab + Lenalidomide and Rituximab (R2) Lenalidomide Participants will receive epcoritamab in combination with R2 during the 120 week treatment duration. Arm B: Chemoimmunotherapy (CIT) Option A Prednisone Participants will receive CIT Option A (obinutuzumab (G) and cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP) \[G-CHOP\]/ rituximab (R)-CHOP during the 120 week treatment duration. Arm A: Epcoritamab + Lenalidomide and Rituximab (R2) Epcoritamab Participants will receive epcoritamab in combination with R2 during the 120 week treatment duration. Arm C: Lenalidomide and Rituximab (R2) Lenalidomide Participants will receive lenalidomide and rituximab (R2) during the 120 week treatment duration. Arm B: Chemoimmunotherapy (CIT) Option A Obinutuzumab Participants will receive CIT Option A (obinutuzumab (G) and cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP) \[G-CHOP\]/ rituximab (R)-CHOP during the 120 week treatment duration. Arm B: Chemoimmunotherapy (CIT) Option B Prednisone Participants will receive CIT Option B (G and bendamustine (Benda) \[G-Benda\]/R-Benda during the 120 week treatment duration. Arm A: Epcoritamab + Lenalidomide and Rituximab (R2) Rituximab Participants will receive epcoritamab in combination with R2 during the 120 week treatment duration. Arm B: Chemoimmunotherapy (CIT) Option A Rituximab Participants will receive CIT Option A (obinutuzumab (G) and cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP) \[G-CHOP\]/ rituximab (R)-CHOP during the 120 week treatment duration. Arm B: Chemoimmunotherapy (CIT) Option A Vincristine Participants will receive CIT Option A (obinutuzumab (G) and cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP) \[G-CHOP\]/ rituximab (R)-CHOP during the 120 week treatment duration. Arm B: Chemoimmunotherapy (CIT) Option A Doxorubicin Participants will receive CIT Option A (obinutuzumab (G) and cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP) \[G-CHOP\]/ rituximab (R)-CHOP during the 120 week treatment duration. Arm B: Chemoimmunotherapy (CIT) Option A Cyclophosphamide Participants will receive CIT Option A (obinutuzumab (G) and cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP) \[G-CHOP\]/ rituximab (R)-CHOP during the 120 week treatment duration. Arm B: Chemoimmunotherapy (CIT) Option B Obinutuzumab Participants will receive CIT Option B (G and bendamustine (Benda) \[G-Benda\]/R-Benda during the 120 week treatment duration. Arm B: Chemoimmunotherapy (CIT) Option B Bendamustine Participants will receive CIT Option B (G and bendamustine (Benda) \[G-Benda\]/R-Benda during the 120 week treatment duration. Arm B: Chemoimmunotherapy (CIT) Option B Rituximab Participants will receive CIT Option B (G and bendamustine (Benda) \[G-Benda\]/R-Benda during the 120 week treatment duration. Arm C: Lenalidomide and Rituximab (R2) Rituximab Participants will receive lenalidomide and rituximab (R2) during the 120 week treatment duration.
- Primary Outcome Measures
Name Time Method Arm A vs Arm B: Number of Participants with Progression-free survival (PFS) Up to 10 Years PFS is defined as the time from randomization until disease progression determined by Lugano 2014 criteria per IRC, or death, whichever occurs first.
Arm A vs Arm B: Percentage of Participants who Achieve Complete Response rate at 30 months (CR30) Up to 30 Months CR30 will be determined by positron emission tomography-computerized tomography (cat scan) \[PET-CT\] per Lugano 2014 criteria, as assessed by independent review committee (IRC).
- Secondary Outcome Measures
Name Time Method Arm A vs Arm B: Overall Survival (OS) Up to 10 Years OS is defined as the time from the date of randomization to the date of death of any cause.
Arm A vs Arm B: Percentage of Participants who Maintain Physical Functioning (PF) According to European Organization for Research and Treatment of Cancer Quality of Life Questionnaire for Cancer (EORTC QLQ-C30) 25 Weeks The PF of EORTC QLQ-C30 is a 5-item questionnaire to assess the physical function of the participant, with a higher score indication worse functioning.
Arm A vs Arm B: Percentage of Participants who Achieve CR30 Up to 30 Months CR30 will be determined by PET-CT per Lugano 2014 criteria, as assessed by investigator.
Arm A vs Arm B: Percentage of Participants with Change in CR Rate per Investigator Up to 10 Years CR will be determined by PET-CT per Lugano 2014 criteria, as assessed by investigator.
Arm A vs Arm C: Number of Participants with BOR per Investigator Up to 10 Years BOR is defined as the percentage of participants who achieve CR or PR determined by Lugano 2014 criteria as assessed by investigator, or death from any cause.
Arm A vs Arm B: Number of Participants with Event-free Survival (EFS) per IRC Up to 10 Years EFS is defined as the time from randomization until adverse event determined by Lugano 2014 criteria per IRC, or death, whichever occurs first.
Arm A vs Arm B: Number of Participants with EFS per Investigator Up to 10 Years EFS is defined as the time from randomization until adverse event determined by Lugano 2014 criteria per investigator, or death, whichever occurs first.
Arm A vs Arm C: Number of Participants with EFS per Investigator Up to 10 Years EFS is defined as the time from randomization until adverse event determined by Lugano 2014 criteria per investigator, or death, whichever occurs first.
Arm A vs Arm C: DOR per IRC Up to 10 Years DOR is defined as the time from PR or CR to disease progression per Lugano 2014 criteria, as assessed by IRC.
Arm A vs Arm B: Rate of Minimal Residual Disease (MRD) Negativity Rate Up to 10 Years MRD negativity rate, defined as the absence of tumor specific molecules in whole blood and/or bone marrow in participants with follicular lymphoma (FL) MRD at baseline.
Arm A vs Arm C: Number of Participants with PFS Up to 10 Years PFS is defined as the time from randomization until disease progression determined by Lugano 2014 criteria per investigator, or death, whichever occurs first.
Arm A vs Arm C: Number of Participants with BOR per IRC Up to 10 Years BOR is defined as the percentage of participants who achieve CR or PR determined by Lugano 2014 criteria as assessed by IRC, or death from any cause.
Arm A vs Arm C: Percentage of Participants who Achieve CR30 Up to 30 Months CR30 will be determined by PET-CT per Lugano 2014 criteria, as assessed by investigator.
Arm A vs Arm C: OS Up to 10 Years OS is defined as the time from the date of randomization to the date of death of any cause.
Arm A vs Arm C: Rate of MRD Negativity Up to 10 Years MRD negativity, defined as the absence of tumor specific molecules in whole blood and/or bone marrow in participants with FL MRD at baseline.
Arm A vs Arm C: Percentage of Participants who Maintain PF According to EORTC QLQ-C30 Up to 10 Years The PF of EORTC QLQ-C30 is a 5-item questionnaire to assess the physical function of the participant, with a higher score indication worse functioning.
Arm A vs Arm B: Percentage of Participants with Change in CR Rate per IRC Up to 10 Years CR will be determined by PET-CT per Lugano 2014 criteria, as assessed by IRC.
Arm A vs Arm C: Percentage of Participants with Change in CR Rate per IRC Up to 10 Years CR will be determined by PET-CT per Lugano 2014 criteria, as assessed by IRC.
Arm A vs Arm C: Percentage of Participants with Change in CR Rate per Investigator Up to 10 Years CR will be determined by PET-CT per Lugano 2014 criteria, as assessed by investigator.
Arm A vs Arm B: Number of Participants with BOR per IRC Up to 10 Years BOR is defined as the percentage of participants who achieve CR or PR determined by Lugano 2014 criteria as assessed by IRC, or death from any cause.
Arm A vs Arm B: Number of Participants with Best Overall Response (BOR) per per Investigator Up to 10 Years BOR is defined as the percentage of participants who achieve CR or partial response (PR) determined by Lugano 2014 criteria as assessed by investigator, or death from any cause.
Arm A vs Arm C: DOCR per IRC Up to 10 Years DOCR is defined as the time from CR to disease progression per Lugano 2014 criteria, as assessed by IRC.
Arm A vs Arm B: Change in Quality of Life (QoL) as Measured by FACT-Lym Up to 10 Years The objective of the FACT-Lym PRO is to assess health-related quality of life issues for adult lymphoma patients. It utilizes a 5-point Likert-type scale.
Arm A vs Arm C: Number of Participants with EFS per IRC Up to 10 Years EFS is defined as the time from randomization until adverse event determined by Lugano 2014 criteria per IRC, or death, whichever occurs first.
Arm A vs Arm B: Duration of Response (DOR) per IRC Up to 10 Years DOR is defined as the time from PR or CR to disease progression per Lugano 2014 criteria, as assessed by IRC.
Arm A vs Arm B: DOCR per Investigator Up to 10 Years DOCR is defined as the time from CR to disease progression per Lugano 2014 criteria, as assessed by investigator.
Arm A vs Arm C: Change in Tolerability as Measured by PRO-CTCAE Up to 10 Years The PRO-CTCAE is a patient-reported outcome measurement system developed to assess symptomatic toxicity in participants in cancer clinical trials. PRO-CTCAE items evaluate common symptoms from study treatment on their frequency, severity, interference, amount, presence/absence.
Arm A vs Arm C: Change in QoL as Measured by FACT-Lym Up to 10 Years The objective of the FACT-Lym PRO is to assess health-related quality of life issues for adult lymphoma patients. It utilizes a 5-point Likert-type scale.
Arm A vs Arm B: Change in Participant Belief in in Efficacy of Treatment as Measured by Patient Global Impression of Change (PGIC) Up to 10 Years The self-report measure PGIC reflects a participant's belief about the efficacy of treatment. The PGIC is a 7-point scale depicting a participant's rating of overall improvement since start of treatment. Participants rate their change as very much improved, much improved, minimally improved, no change, minimally worse, much worse, or very much worse.
Arm A vs Arm B: Duration of Complete Response (DOCR) per IRC Up to 10 Years DOCR is defined as the time from CR to disease progression per Lugano 2014 criteria, as assessed by IRC.
Arm A vs Arm C: DOCR per Investigator Up to 10 Years DOCR is defined as the time from CR to disease progression per Lugano 2014 criteria, as assessed by investigator.
Arm A vs Arm B: Time to Next Anti-lymphoma Therapy (TTNT) Up to 10 Years TTNT is defined as the time from randomization to first documented administration of subsequent anti-lymphoma therapy
Arm A vs Arm B: Time to Progression per Investigator Up to 10 Years Time to progression defined as the time from randomization to disease progression per Lugano 2014 criteria, as assessed by investigator.
Arm A vs Arm C: Time to Progression per Investigator Up to 10 Years Time to progression defined as the time from randomization to disease progression per Lugano 2014 criteria, as assessed by investigator.
Arm A vs Arm C: Number of Participants with PFS2 Up to 10 Years PFS2 is defined as the time after subsequent anti-lymphoma therapy to the earliest occurrence of disease progression determined by Lugano 2014 criteria as assessed by investigator, or death from any cause.
Arm A vs Arm C: Change in QoL as Measured by EQ-5D-5L Up to 10 Years The EQ-5D-5L is a standardized, non-disease specific instrument used to measure health-related quality of life. The EQ-5D-5L assesses general health on 5 dimensions (mobility, self-care, usual activities, pain/discomfort and anxiety/depression). Each dimension has 5 levels (no problems, slight problems, moderate problems, severe problems, and extreme problem...
Arm A vs Arm C: Change in Participant Belief in in Efficacy of Treatment as Measured by PGIS Up to 10 Years The self-report measure PGIS reflects a participant's belief about their lymphoma symptoms over the past 7 days. The PGIS is a 5-point scale depicting a participant's rating of overall severity.
Arm A vs Arm B: DOR per Investigator Up to 10 Years DOR is defined as the time from PR or CR to disease progression per Lugano 2014 criteria, as assessed by investigator.
Arm A vs Arm C: TTNT Up to 10 Years TTNT is defined as the time from randomization to first documented administration of subsequent anti-lymphoma therapy
Arm A vs Arm B: Time to Progression per IRC Up to 10 Years Time to progression defined as the time from randomization to disease progression per Lugano 2014 criteria, as assessed by IRC.
Arm A vs Arm B: Change in Symptoms as Measured by The Functional Assessment of Cancer Therapy - Lymphoma (FACT-Lym) Up to 10 Years The objective of the FACT-Lym patient reported outcome (PRO) is to assess health-related quality of life issues for adult lymphoma patients. It utilizes a 5-point Likert-type scale.
Arm A vs Arm B: Change in QoL as Measured by 5-Level European Quality of Life (EuroQol)-5-dimension [EQ-5D-5L] Up to 10 Years The EQ-5D-5L is a standardized, non-disease specific instrument used to measure health-related quality of life. The EQ-5D-5L assesses general health on 5 dimensions (mobility, self-care, usual activities, pain/discomfort and anxiety/depression). Each dimension has 5 levels (no problems, slight problems, moderate problems, severe problems, and extreme problem...
Arm A vs Arm C: Change in Participant Belief in in Efficacy of Treatment as Measured by PGIC Up to 10 Years The self-report measure PGIC reflects a participant's belief about the efficacy of treatment. The PGIC is a 7-point scale depicting a participant's rating of overall improvement since start of treatment. Participants rate their change as very much improved, much improved, minimally improved, no change, minimally worse, much worse, or very much worse.
Arm A vs Arm C: DOR per Investigator Up to 10 Years DOR is defined as the time from PR or CR to disease progression per Lugano 2014 criteria, as assessed by investigator.
Arm A vs Arm C: Time to Progression per IRC Up to 10 Years Time to progression defined as the time from randomization to disease progression per Lugano 2014 criteria, as assessed by IRC.
Arm A vs Arm B: Number of Participants with Progression-free Survival After Subsequent Anti-Lymphoma Therapy (PFS2) Up to 10 Years PFS2 is defined as the time after subsequent anti-lymphoma therapy to the earliest occurrence of disease progression determined by Lugano 2014 criteria as assessed by investigator, or death from any cause.
Arm A vs Arm B: Change in Tolerability as Measured by Patient Reported Outcomes-Common Terminology Criteria for Adverse Events (PRO-CTCAE) Up to 10 Years The PRO-CTCAE is a patient-reported outcome measurement system developed to assess symptomatic toxicity in participants in cancer clinical trials. PRO-CTCAE items evaluate common symptoms from study treatment on their frequency, severity, interference, amount, presence/absence.
Arm A vs Arm B: Change in Tolerability as Measured by The Functional Assessment of Cancer Therapy Singly Item - GP5 (FACT-GP5) Up to 10 Years The FACT-GP5 is a single question asking if participant is bothered by side effects of treatment.
Arm A vs Arm C: Change in Tolerability as Measured by FACT-GP5 Up to 10 Years The FACT-GP5 is a single question asking if participant is bothered by side effects of treatment.
Arm A vs Arm C: Change in Symptoms as Measured by FACT-Lym Up to 10 Years The objective of the FACT-Lym patient reported outcome (PRO) is to assess health-related quality of life issues for adult lymphoma patients. It utilizes a 5-point Likert-type scale.
Arm A vs Arm B: Change in Participant Belief in in Efficacy of Treatment as Measured by Patient Global Impression of Severity (PGIS) Up to 10 Years The self-report measure PGIS reflects a participant's belief about their lymphoma symptoms over the past 7 days. The PGIS is a 5-point scale depicting a participant's rating of overall severity.
Trial Locations
- Locations (195)
Rocky Mountain Cancer Centers - Boulder /ID# 261203
🇺🇸Boulder, Colorado, United States
Christiana Care Health Service /ID# 261207
🇺🇸Newark, Delaware, United States
Oncology Hematology Care, Inc - Blue Ash /ID# 261204
🇺🇸Cincinnati, Ohio, United States
Oncology Associates of Oregon, P.C. /ID# 261816
🇺🇸Eugene, Oregon, United States
Texas Oncology - Austin Midtown /ID# 261208
🇺🇸Austin, Texas, United States
Texas Oncology- Baylor Charles A. Sammons Cancer Center /ID# 261206
🇺🇸Dallas, Texas, United States
Virginia Cancer Specialists - Fairfax /ID# 261205
🇺🇸Fairfax, Virginia, United States
Oncology and Hematology Associates of Southwest Virginia /ID# 261592
🇺🇸Roanoke, Virginia, United States
Zhujiang Hospital of Southern Medical University /ID# 260558
🇨🇳Guangzhou, Guangdong, China
Affiliated Cancer Hospital of Guangxi Medical University /ID# 260537
🇨🇳Nanning, Guangxi, China
Union Hospital affiliated to Tongji Medical College of Huazhong University of Sc /ID# 259743
🇨🇳Wuhan, Hubei, China
Fudan University Cancer Hospital /ID# 260564
🇨🇳Shanghai, Shanghai, China
Tianjin Cancer Hospital /ID# 259807
🇨🇳Tianjin, Tianjin, China
Fakultní nemocnice Hradec Králové - Sokolská /ID# 260560
🇨🇿Hradec Králové, Hradec Kralove, Czechia
Regionshospitalet Godstrup /ID# 260778
🇩🇰Herning, Midtjylland, Denmark
IRCCS AOU di Bologna - Policlinico Sant'Orsola-Malpighi /ID# 260886
🇮🇹Bologna, Emilia-Romagna, Italy
Fondazione Policlinico Universitario Campus Bio-Medico /ID# 260891
🇮🇹Roma, Italy
Tokyo Metropolitan Komagome Hospital /ID# 267692
🇯🇵Bunkyo ku, Tokyo, Japan
Elisabeth Tweesteden Ziekenhuis /ID# 261239
🇳🇱Tilburg, Noord-Brabant, Netherlands
Rijnstate /ID# 261219
🇳🇱Arnhem, Netherlands
Swietokrzyskie Centrum Onkologii Samodzielny Publiczny Zaklad Opieki Zdrowotnej /ID# 260170
🇵🇱Kielce, Swietokrzyskie, Poland
Haemalife Inc. /ID# 260513
🇿🇦Kuilsrivier, Western Cape, South Africa
Institut Català d'Oncologia (ICO) - L'Hospitalet /ID# 261439
🇪🇸L'Hospitalet de Llobregat, Barcelona, Spain
Hammersmith Hospital /ID# 261124
🇬🇧London, England, United Kingdom
Leeds Teaching Hospitals NHS Trust /ID# 260466
🇬🇧Leeds, West Yorkshire, United Kingdom
The Christie Hospital /ID# 260463
🇬🇧Manchester, United Kingdom
Cancer Specialists of North Florida /ID# 262445
🇺🇸Jacksonville, Florida, United States
Advent Health /ID# 261578
🇺🇸Orlando, Florida, United States
Orlando Health Cancer Institute /ID# 260983
🇺🇸Orlando, Florida, United States
Beacon Cancer Care /ID# 260670
🇺🇸Coeur d'Alene, Idaho, United States
Illinois Cancer Care, PC /ID# 261526
🇺🇸Peoria, Illinois, United States
Fort Wayne Medical Oncology and Hematology- South Office /ID# 259583
🇺🇸Fort Wayne, Indiana, United States
Mission Cancer and Blood /ID# 262132
🇺🇸Des Moines, Iowa, United States
University of Louisville Hospital /ID# 260544
🇺🇸Louisville, Kentucky, United States
Norton Cancer Institute - St. Matthews /ID# 261076
🇺🇸Louisville, Kentucky, United States
New England Cancer Specialists - Scarborough /ID# 260672
🇺🇸Scarborough, Maine, United States
University of Maryland, Baltimore /ID# 259538
🇺🇸Baltimore, Maryland, United States
American Oncology Partners of Maryland /ID# 259476
🇺🇸Bethesda, Maryland, United States
St. Luke's Hospital - Chesterfield /ID# 260489
🇺🇸Chesterfield, Missouri, United States
Intermountain Health St. Vincent Regional Hospital - Cancer Centers of Montana /ID# 260006
🇺🇸Billings, Montana, United States
Nebraska Cancer Specialists (NCS) - Regional Cancer Center - St Francis Location /ID# 262506
🇺🇸Grand Island, Nebraska, United States
Nebraska Cancer Specialists - Omaha - Wright Street /ID# 262505
🇺🇸Omaha, Nebraska, United States
University of Nebraska Medical Center /ID# 261996
🇺🇸Omaha, Nebraska, United States
University of New Mexico /ID# 261083
🇺🇸Albuquerque, New Mexico, United States
Presbyterian Kaseman Hospital /ID# 262451
🇺🇸Albuquerque, New Mexico, United States
Presbyterian Rust Medical Center /ID# 262447
🇺🇸Rio Rancho, New Mexico, United States
New York Oncology Hematology - Albany Cancer Center /ID# 261814
🇺🇸Albany, New York, United States
Icahn School of Medicine at Mount Sinai /ID# 259595
🇺🇸New York, New York, United States
New York Oncology Hematology /ID# 270208
🇺🇸Troy, New York, United States
Clinical Research Alliance, Inc. /ID# 261078
🇺🇸Westbury, New York, United States
Taylor Cancer Research Center /ID# 260488
🇺🇸Maumee, Ohio, United States
MUSC Hollings Cancer Center /ID# 259604
🇺🇸Charleston, South Carolina, United States
Prisma Health /ID# 259602
🇺🇸Greenville, South Carolina, United States
MD Anderson Cancer Center /ID# 260984
🇺🇸Houston, Texas, United States
Oncology Consultants /ID# 268390
🇺🇸Houston, Texas, United States
Joe Arrington Cancer Research /ID# 260382
🇺🇸Lubbock, Texas, United States
Intermountain Healthcare LDS Hospital /ID# 259759
🇺🇸Salt Lake City, Utah, United States
Vista Oncology - East Olympia /ID# 261360
🇺🇸Olympia, Washington, United States
Virginia Mason Hospital & Medical Center /ID# 260549
🇺🇸Seattle, Washington, United States
Royal Prince Alfred Hospital /ID# 259320
🇦🇺Camperdown, New South Wales, Australia
Liverpool Hospital /ID# 259321
🇦🇺Liverpool, New South Wales, Australia
Peter MacCallum Cancer Center /ID# 260431
🇦🇺Melbourne, New South Wales, Australia
Westmead Hospital /ID# 261465
🇦🇺Westmead, New South Wales, Australia
Townsville University Hospital /ID# 259323
🇦🇺Douglas, Queensland, Australia
Royal Brisbane and Women's Hospital /ID# 259326
🇦🇺Herston, Queensland, Australia
Princess Alexandra Hospital /ID# 259329
🇦🇺Woolloongabba, Queensland, Australia
Peninsula Private Hospital /ID# 259325
🇦🇺Frankston, Victoria, Australia
Fiona Stanley Hospital /ID# 259324
🇦🇺Murdoch, Western Australia, Australia
Royal Perth Hospital /ID# 259319
🇦🇺Perth, Western Australia, Australia
Algemeen Ziekenhuis klina /ID# 260324
🇧🇪Brasschaat, Antwerpen, Belgium
Cliniques Universitaires UCL Saint-Luc /ID# 260311
🇧🇪Woluwe-Saint-Lambert, Bruxelles-Capitale, Belgium
UZ Gent /ID# 260312
🇧🇪Gent, Oost-Vlaanderen, Belgium
AZ-Delta /ID# 260313
🇧🇪Roeselare, West-Vlaanderen, Belgium
Groupe Sante CHC - Clinique du MontLegia /ID# 260325
🇧🇪Liege, Belgium
UMHAT Dr Georgi Stranski EAD /ID# 260763
🇧🇬Pleven, Bulgaria
Acibadem City Clinic Tokuda University Hospital EAD /ID# 260685
🇧🇬Sofia, Bulgaria
UMHAT Sveti Ivan Rilski /ID# 259277
🇧🇬Sofia, Bulgaria
SHAT Hematologic Diseases /ID# 260457
🇧🇬Sofia, Bulgaria
Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sc /ID# 259616
🇨🇳Tianjin, Tianjin, China
Clinical Hospital Dubrava /ID# 260452
🇭🇷Zagreb, Grad Zagreb, Croatia
Klinicka bolnica Merkur /ID# 260393
🇭🇷Zagreb, Grad Zagreb, Croatia
Klinicki bolnicki centar Sestre milosrdnice /ID# 260456
🇭🇷Zagreb, Grad Zagreb, Croatia
Klinicki bolnicki centar Zagreb /ID# 260364
🇭🇷Zagreb, Grad Zagreb, Croatia
Klinicki bolnicki centar Rijeka /ID# 260455
🇭🇷Rijeka, Primorsko-goranska Zupanija, Croatia
Klinicki Bolnicki Centar (KBC) Split /ID# 260454
🇭🇷Split, Splitsko-dalmatinska Zupanija, Croatia
Zadar General Hospital /ID# 260837
🇭🇷Zadar, Croatia
Fakultni nemocnice Kralovske Vinohrady /ID# 260572
🇨🇿Praha, Czechia
Roskilde Sygehus /ID# 260780
🇩🇰Roskilde, Sjælland, Denmark
Odense University Hospital /ID# 260777
🇩🇰Odense, Syddanmark, Denmark
Sygehus Lillebalt, Vejle /ID# 260781
🇩🇰Vejle, Syddanmark, Denmark
Hopital Prive du Confluent /ID# 260596
🇫🇷Nantes CEDEX 2, Loire-Atlantique, France
Centre Hospitalier D'Avignon /ID# 260511
🇫🇷Avignon, Provence-Alpes-Cote-d Azur, France
HCL - Hopital Lyon Sud /ID# 260508
🇫🇷Pierre Benite CEDEX, Rhone, France
Centre Hospitalier du Mans /ID# 260510
🇫🇷Le Mans CEDEX 9, Sarthe, France
CHU de CAEN - Hopital de la Cote de Nacre /ID# 260875
🇫🇷Caen, France
CH Libourne - Hopital Robert Boulin /ID# 261478
🇫🇷Libourne, France
Hôpital Saint-Louis /ID# 260509
🇫🇷Paris, France
Clinique Sainte-Anne /ID# 261528
🇫🇷Strasbourg, France
Hadassah /ID# 259935
🇮🇱Jerusalem, Yerushalayim, Israel
Städtisches Klinikum Karlsruhe /ID# 260348
🇩🇪Karlsruhe, Baden-Wuerttemberg, Germany
Universitaetsklinikum Frankfurt /ID# 260388
🇩🇪Frankfurt am Main, Hessen, Germany
Klinikum Kassel /ID# 260432
🇩🇪Kassel, Hessen, Germany
St.-Antonius-Hospital /ID# 260520
🇩🇪Eschweiler, Nordrhein-Westfalen, Germany
Klinikum Ludwigshafen /ID# 260688
🇩🇪Ludwigshafen am Rhein, Rheinland-Pfalz, Germany
Otto-von-Guericke-Universitaet /ID# 260425
🇩🇪Magdeburg, Germany
Olympion General Clinic /ID# 262395
🇬🇷Patras, Achaia, Greece
General Hospital of Athens Laiko /ID# 259708
🇬🇷Athens, Attiki, Greece
University General Hospital Attikon /ID# 260855
🇬🇷Athens, Attiki, Greece
General University Hospital of Alexandroupolis /ID# 260858
🇬🇷Alexandroupolis, Greece
General Hospital of Athens Evaggelismos and Ophthalmiatrio of Athens Polyclinic /ID# 259709
🇬🇷Athens, Greece
Gyor-Moson-Sopron Varmegyei Petz Aladar Egyetemi Oktato Korhaz /ID# 260051
🇭🇺Gyor, Gyor-Moson-Sopron, Hungary
Tolna Varmegyei Balassa Janos Korhaz /ID# 260048
🇭🇺Szekszard, Tolna, Hungary
Vas Varmegyei Markusovszky Egyetemi Oktatokorhaz /ID# 260050
🇭🇺Szombathely, Vas, Hungary
Orszagos Onkologiai Intezet /ID# 260052
🇭🇺Budapest, Hungary
HaEmek Medical Center /ID# 259936
🇮🇱Afula, H_efa, Israel
Soroka University Medical Center /ID# 259937
🇮🇱Be'er Sheva, HaDarom, Israel
Meir Medical Center /ID# 259938
🇮🇱Kfar Saba, HaMerkaz, Israel
The Chaim Sheba Medical Center /ID# 259934
🇮🇱Ramat Gan, Tel-Aviv, Israel
Tel Aviv Sourasky Medical Center /ID# 259933
🇮🇱Tel Aviv, Tel-Aviv, Israel
Rabin Medical Center /ID# 268328
🇮🇱Haifa, Israel
Istituto di Candiolo Fondazione del Piemonte per l'Oncologia IRCCS /ID# 260889
🇮🇹Candiolo, Torino, Italy
Azienda Ospedaliera Ospedali Riuniti Villa Sofia Cervello /ID# 260888
🇮🇹Palermo, Italy
AUSL di Reggio Emilia - Arcispedale Santa Maria Nuova /ID# 260744
🇮🇹Reggio Emilia, Italy
Fujita Health University Hospital /ID# 264679
🇯🇵Toyoake, Aichi, Japan
Matsuyama Red Cross Hospital /ID# 266426
🇯🇵Matsuyama-shi, Ehime, Japan
University of Fukui Hospital /ID# 265680
🇯🇵Yoshida-gun, Fukui, Japan
National Hospital Organization Kyushu Cancer Center /ID# 265960
🇯🇵Fukuoka-shi, Fukuoka, Japan
Fukushima Medical University Hospital /ID# 264994
🇯🇵Fukushima-shi, Fukushima, Japan
Chugoku Central Hospital /ID# 266520
🇯🇵Fukuyama, Hiroshima, Japan
Sapporo Medical University Hospital /ID# 265031
🇯🇵Sapporo, Hokkaido, Japan
Kobe City Medical Center General Hospital /ID# 266379
🇯🇵Kobe-shi, Hyogo, Japan
Hitachi General Hospital /ID# 265676
🇯🇵Hitachi, Ibaraki, Japan
Kitasato University Hospital /ID# 264675
🇯🇵Sagamihara, Kanagawa, Japan
Kanagawa Cancer Center /ID# 265497
🇯🇵Yokohama-shi, Kanagawa, Japan
Okayama University Hospital /ID# 267135
🇯🇵Okayama-shi, Okayama, Japan
Kansai Medical University Hospital /ID# 266019
🇯🇵Hirakata-shi, Osaka, Japan
Kindai University Hospital /ID# 265038
🇯🇵Osakasayama-shi, Osaka, Japan
The University of Tokyo Hospital /ID# 266422
🇯🇵Bunkyo-ku, Tokyo, Japan
Yamaguchi University Hospital /ID# 265619
🇯🇵Ube, Yamaguchi, Japan
University of Yamanashi Hospital /ID# 264677
🇯🇵Chuo, Yamanashi, Japan
Aomori Prefectural Central Hospital /ID# 265692
🇯🇵Aomori, Japan
Chiba Cancer Center /ID# 267316
🇯🇵Chiba, Japan
Seoul National University Bundang Hospital /ID# 260009
🇰🇷Seongnam-si, Gyeonggido, Korea, Republic of
Seoul National University Hospital /ID# 260007
🇰🇷Seoul, Seoul Teugbyeolsi, Korea, Republic of
Asan Medical Center /ID# 260010
🇰🇷Seoul, Seoul Teugbyeolsi, Korea, Republic of
Samsung Medical Center /ID# 260008
🇰🇷Seoul, Seoul Teugbyeolsi, Korea, Republic of
Bravis Ziekenhuis /ID# 259055
🇳🇱Bergen op Zoom, Noord-Brabant, Netherlands
Olvg /Id# 259543
🇳🇱Amsterdam, Noord-Holland, Netherlands
St. Antonius Ziekenhuis /ID# 259053
🇳🇱Nieuwegein, Utrecht, Netherlands
HagaZiekenhuis /ID# 261220
🇳🇱Den Haag, Zuid-Holland, Netherlands
Leids Universitair Medisch Centrum /ID# 259049
🇳🇱Leiden, Zuid-Holland, Netherlands
Franciscus Gasthuis & Vlietland, Locatie Gasthuis /ID# 259052
🇳🇱Rotterdam, Zuid-Holland, Netherlands
Universitair Medisch Centrum Groningen /ID# 259051
🇳🇱Groningen, Netherlands
Auckland City Hospital /ID# 259330
🇳🇿Grafton, Auckland, New Zealand
North Shore Hospital /ID# 260824
🇳🇿Takapuna, Auckland, New Zealand
Wojewódzkie Wielospecjalistyczne Centrum Onkologii i Traumatologii im. M. Kopern /ID# 260633
🇵🇱Lodz, Lodzkie, Poland
Pratia MCM Krakow /ID# 260075
🇵🇱Krakow, Malopolskie, Poland
Narodowy Instytut Onkologii im. M. Sklodowskiej /ID# 260861
🇵🇱Warszawa, Mazowieckie, Poland
Fundacao Champalimaud /ID# 259652
🇵🇹Lisbon, Lisboa, Portugal
Unidade Local de Saude de Gaia/Espinho, EPE /ID# 259655
🇵🇹Vila Nova de Gaia, Porto, Portugal
Unidade Local de Saude de Santa Maria, EPE /ID# 259650
🇵🇹Lisboa, Portugal
Instituto Portugues de Oncologia do Porto Francisco Gentil, EPE /ID# 259649
🇵🇹Porto, Portugal
Pan American Center for Oncology Trials, LLC /ID# 260265
🇵🇷Rio Piedras, Puerto Rico
Auxilio Mutuo Cancer Center /ID# 260262
🇵🇷San Juan, Puerto Rico
Fundeni Clinical Institute /ID# 260296
🇷🇴Bucharest, Bucuresti, Romania
Institutul Oncologic Prof Dr I Chiricuta /ID# 259704
🇷🇴Cluj Napoca, Cluj, Romania
Institutul Regional de Oncologie /ID# 259697
🇷🇴Jassi, Iasi, Romania
Spitalul Clinic Coltea /ID# 259699
🇷🇴Bucharest, Romania
Clinical Hospital Center Zvezdara /ID# 260900
🇷🇸Belgrade, Beograd, Serbia
University Clinical Center Serbia /ID# 259271
🇷🇸Belgrade, Beograd, Serbia
University Clinical Center Kragujevac /ID# 259274
🇷🇸Kragujevac, Pomoravski Okrug, Serbia
Institute for Oncology of Vojvodina /ID# 260223
🇷🇸Sremska Kamenica, Vojvodina, Serbia
University Clinical Center Vojvodina /ID# 259272
🇷🇸Novi Sad, Serbia
Narodny onkologicky ustav /ID# 260638
🇸🇰Bratislava, Bratislavsky Kraj, Slovakia
Univerzitna nemocnica Martin /ID# 260631
🇸🇰Martin, Zilinsky Kraj, Slovakia
Alberts Cellular Therapy /ID# 260514
🇿🇦Pretoria, Gauteng, South Africa
Instituto Catalan de Oncologia (ICO) Badalona /ID# 260495
🇪🇸Badalona, Barcelona, Spain
Hospital Universitario Marques de Valdecilla /ID# 260497
🇪🇸Santander, Cantabria, Spain
Clinica Universidad de Navarra - Pamplona /ID# 260496
🇪🇸Pamplona, Navarra, Spain
Hospital Universitario Vall d'Hebron /ID# 260490
🇪🇸Barcelona, Spain
Hospital Clinic de Barcelona /ID# 260492
🇪🇸Barcelona, Spain
Hospital Santa Creu i Sant Pau /ID# 260498
🇪🇸Barcelona, Spain
Hospital San Pedro de Alcantara /ID# 260502
🇪🇸Caceres, Spain
CLINICA UNIVERSIDAD DE NAVARRA-Madrid /ID# 261512
🇪🇸Madrid, Spain
MD Anderson Madrid /ID# 260500
🇪🇸Madrid, Spain
Hospital Universitario de Salamanca /ID# 260491
🇪🇸Salamanca, Spain
Sodra Alvsborgs sjukhus /ID# 261168
🇸🇪Boras, Vastra Gotalands Lan, Sweden
National Taiwan University Hospital /ID# 260341
🇨🇳Taipei City, Taipei, Taiwan
China Medical University Hospital /ID# 260357
🇨🇳Taichung, Taiwan
Taichung Veterans General Hospital /ID# 260361
🇨🇳Taichung, Taiwan
National Cheng Kung University Hospital /ID# 260363
🇨🇳Tainan, Taiwan
Kocaeli University Med Faculty /ID# 259717
🇹🇷Kocaeli, Turkey
Ondokuz Mayis Universitesi /ID# 259713
🇹🇷Samsun, Turkey
Derriford Hospital and the Royal Eye Infirmary /ID# 262671
🇬🇧Plymouth, Devon, United Kingdom
The Newcastle Upon Tyne Hospitals NHS Foundation Trust /ID# 260792
🇬🇧Newcastle upon Tyne, United Kingdom
Related News
Two Data Analyses from Clinical Trials Show Epcoritamab (DuoBody® CD3xCD20) Induces ...
Two Data Analyses from Clinical Trials Show Epcoritamab (DuoBody® CD3xCD20) Induces ...
Two Data Analyses from Clinical Trials Show Epcoritamab (DuoBody® CD3xCD20) Induces ...
Two Data Analyses From Clinical Trials Show Epcoritamab (DuoBody® CD3xCD20 ... - PR Newswire
Two Data Analyses From Clinical Trials Show Epcoritamab (DuoBody® CD3xCD20 ...
- Prev
- 1
- 2
- 3
- 4
- Next